Title: W3C HCLS Task Force on Drug Safety and Efficacy
1W3C HCLS Task Force on Drug Safety and Efficacy
- Kerstin Forsberg, Bo Anderson, AstraZeneca
- Jim McGurk Merck
- Ted Slater Pfizer
- Eric Neumann Teranode
- Uwe Trinks Sentrx
2Areas
- Translational Science Perspective
- State thinking (biomarkers)
- Safety dimensions
- Efficacy (disease models)
- Animal ? Human
- Clinical Observations relation biomarkers (
mechanisms) - Discovery
- Targets
- Biomarkers
- Therapeutic
- Leads, Candidates
- Mechanisms
- BioPAX
3Domain Semantics
- Clinical Semantics
- Patient ? Disease state
- Diagnostics ? Findings
- Inferred (proposed) Disease state
- Patient Classification / Segmentation
- Clinical trial arm / treatment
- Observation ? POC, safety, mechanism
4July 2004
Announcement of CDISC/SDTMas a standard format
CDISCClinical Data Interchange Standards
Consortium
RCRIM Regulated Clinical Research and
Information Management,technical committee
Relationship HL7/CDISC
HL7 Health Level Seven
5During 2006-2007
SDTM variables asCommon DataElementsControlle
dTerminologies
NCI Thesaurus
In OWL format
CDISCClinical Data Interchange Standards
Consortium
UMLS
RCRIM Regulated Clinical Research and
Information Management,technical committee
Relationship HL7/CDISC
BRIDGBiomedical Research Integrated Domain Group
Model
HL7 Health Level Seven
6Ongoing work at FDA
Announcement of CDISC/SDTMas a standard format
CDISCClinical Data Interchange Standards
Consortium
RCRIM Regulated Clinical Research and
Information Management,technical committee
Relationship HL7/CDISC
Janus Model and Data Warehouse
HL7 Health Level Seven
populate a cross-study database and do more
comprehensive analyses for the benefit of
patients.
7Proposed Notes and Activities
- Notes planned
- SDTM and JANUS from a SW perspective
- Semantic enriched evolvable recombinant clinical
observations - DEMO Table and XML models ala RDF
- Retrospective DBs (JANUS) and SW power of
annotations and links - DEMO using URI code and RDBM
- Provenance and trust (non-reputability)
- ACL?